Trial pipeline
Track psilocybin trial phases, recruitment, sponsors and registry completion dates with country filters, source links, comparison and free data exports.
Free access · No subscription for research tools or data exports
Filter the development pipeline
5 trials match this view; 5 reported facilities; 5 have usable coordinates. Latest indexed registry check Nov 19, 2026 02:23 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.
Enrollment sum: 72 across 5 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.
Recorded study-start years
Current indexed registry status
Reported research conditions
Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.
Milestones to investigate
The table is ordered by reported primary completion date. Check whether the registry calls enrollment estimated or actual, when the record was last updated, and whether results have been published. Completion dates are not readout dates; no model-generated success probabilities are assigned.
For late-stage studies, choose PHASE3 above. For studies still underway, choose an exact recruitment status. Use sponsor and country filters to inspect a programme, then save records to compare their designs.
Matching trial records
| Trial | Sponsor and phase | Status | Enrollment | Start / primary completion / completion | Research workflow |
|---|---|---|---|---|---|
| A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (psilocybin) in Healthy ParticipantsHealthy Volunteers | MycoMedica Life Sciences PBC PHASE1 | Completed Registry updated 2024-10-09 | 24 ACTUAL | 2024-03-27 2024-07-08 2024-07-08 | |
| A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy ParticipantsHealthy Volunteers | MycoMedica Life Sciences PBC PHASE1 | Completed Registry updated 2025-06-12 | 16 ACTUAL | 2024-11-08 2025-03-12 2025-03-12 | |
| Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-samplingPsychedelic Experiences · Neuroimaging · Healthy Volunteers | Robin Carhart-Harris, PhD, MA PHASE1 | Active, not recruiting Registry updated 2026-06-05 | 12 ESTIMATED | 2023-07-31 2026-01-30 2027-01-30 | |
| Open Label Psilocybin Brain Stimulation and Imaging Pilot StudyHealthy Volunteers | Johns Hopkins University PHASE1 | Completed Registry updated 2026-08-07 | 10 ACTUAL | 2025-04-18 2026-05-21 2026-05-21 | |
| Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy VolunteersHealthy Volunteers | Hadassah Medical Organization PHASE1 | Recruiting Registry updated 2026-02-05 | 10 ESTIMATED | 2025-12-11 2026-11 2027-02 |
Reported research facilities
CMAX Clinical ResearchAdelaide, South Australia, Australia · Coordinates available
CMAX Clinical Research Pty LtdAdelaide, South Australia, Australia · Coordinates available
Hadassah Medical Organization, Jerusalem, IsraelJerusalem, Israel · Coordinates available
Johns Hopkins School of MedicineBaltimore, Maryland, United States · Coordinates available
University of California, San FranciscoSan Francisco, California, United States · Coordinates available
This directory includes reported facilities with and without coordinates. For a country-filtered view, locations are labeled as selected-country sites or international sites of matching trials. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.